HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
The PERT Consortium shared a proud post on X:
”We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of intermediate-high risk PE patients. The study was a collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific. We extend our congratulations to all investigators and enrollment sites involved in this one-of-a-kind trial that will inform strategies for PE treatment around the world.”
Learn more abouth the HI-PEITHO here.
Enrollment for the HIPEITHO trial has successfully concluded, with 544 patients enrolled across 72 clinical sites in the United States and Europe.
In HIPEITHO Trial, the pivotal, multicenter study compares ultrasound-assisted catheter-directed thrombolysis using the EKOS system plus anticoagulation versus anticoagulation alone in patients with intermediate-high risk pulmonary embolism (PE).
A collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific, HIPEITHO trial represents a major step forward in evaluating treatment strategies for PE.
The results are expected to significantly inform clinical decision-making and global PE management.
Congratulations to all investigators and sites for their contribution to this groundbreaking trial!
Find the latest scientific advancements in thrombosis management featured in Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology